AstraZeneca shares slide after heart drug trial misses key target
A late-stage setback for AstraZeneca's cardiovascular pipeline is sending its shares sharply lower in London trading. The company says Wainua fails to meet the main goal in a study for a rare heart condition, raising questions about the treatment's commercial outlook.
Highlights
- AstraZeneca's experimental heart drug Wainua failed to meet its primary endpoint in a late-stage ATTR-CM trial over 140 weeks versus placebo.
- AstraZeneca shares dropped as much as 9%, closing down 8.9% in London for their worst trading day since March 2020 following the trial update.
- The missed trial objective for Wainua represents a major setback for AstraZeneca's cardiovascular pipeline and may complicate future program positioning and investor confidence.
Trial outcome and market reaction
As reported by CNBC, citing AstraZeneca in a press release, the experimental medicine Wainua does not achieve its primary endpoint in a late-stage clinical trial for transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM. The study measures whether the drug can reduce deaths and recurrent heart-related emergencies over 140 weeks compared with a placebo.The share decline deepens after the update, with AstraZeneca stock falling as much as 9%. The shares are last down 8.9% in London, putting the company on track for its worst trading day since March 2020, at the start of the Covid-19 outbreak.
Implications for AstraZeneca's heart disease portfolio
Wainua is being developed for a rare and life-threatening heart disease, making the missed objective a significant setback for AstraZeneca's efforts in the specialty cardiovascular market. Failure to meet the study's main target could complicate the drug's future positioning and investor expectations for the program.The result also highlights the development risk tied to late-stage pharmaceutical research, where disappointing trial data can quickly affect valuation and sentiment. For AstraZeneca, the outcome is likely to keep attention on how the company manages its pipeline and whether other programs can offset the pressure from this setback.
In our earlier coverage of Vertex Pharmaceuticals’ $10 billion all-cash acquisition of Crinetics Pharmaceuticals, we looked at how the deal broadened Vertex’s portfolio with the approved drug Palsonify and pipeline candidate Atumelant while raising questions about the near-term impact of the capital outlay. The article also noted that VRTX was trading under key moving averages, with technical signals pointing to seller dominance and a defined near-term trading range as markets weighed integration risk against longer-term pipeline expansion.
Latest AstraZeneca News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
